Study on the allosteric activation mechanism of SHP2 elastic network models and neural relational inference molecular dynamics simulation.

Journal: Physical chemistry chemical physics : PCCP
Published Date:

Abstract

As a ubiquitous protein tyrosine phosphatase, SHP2 is involved in PD-1/PD-L1 mediated tumor immune escape and undergoes substantial conformational changes. Therefore, it is considered an ideal target for tumor intervention. However, the allosteric mechanisms of SHP2 binding PD-1 intracellular ITIM/ITSM phosphopeptides remain unclear, which greatly hinders the development of novel structure-based anticancer allosteric inhibitors. In this work, the open and closed structural models of SHP2 are first constructed based on this knowledge; next their motion modes are investigated elastic network models such as the Gaussian network model (GNM), anisotropic network model (ANM) and adaptive anisotropic network model (aANM); and finally, a possible allosteric signaling pathway is proposed using a neural relational inference molecular dynamics (NRI-MD) simulation embedded with an artificial intelligence (AI) strategy. In GNM and ANM, the N-SH2, C-SH2 and PTP domains all exhibit distinct dynamics partitions, and the N-SH2/C-SH2 regions show a rigid rotation relative to PTP. According to a series of intermediate snapshots given by aANM, N-SH2 is first identified with pY223 specifically, inducing a D'E-loop to change from β-sheets to random coils, and then, C-SH2 serves as a fulcrum to drive N-SH2 to rotate 110° completely away from the original active sites of PTP. Finally, a possible allosteric signaling-transfer path for SHP2, namely R220-R138-T108-R32, is proposed based on NRI-MD sampling. This work provides a possible allosteric mechanism of SHP2, which is helpful for the following design of novel allosteric inhibitors and is expected to be used in clinical synergies with PD-1 monoclonal antibody.

Authors

  • Ling Liu
    College of Mathematics and Statistics, Hubei Normal University, Huangshi 435002, China. Electronic address: lliu9308@sina.com.
  • Yan Cheng
    The First Clinical Medical College of Shaanxi University of Chinese Medicine, Xianyang, China.
  • Zhigang Zhang
    Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, China.
  • Jing Li
    Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Yichao Geng
    Department of Thoracic Oncology, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China. ouyangww73@163.com.
  • Qingsong Li
    Department of Thoracic Oncology, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China. ouyangww73@163.com.
  • Daxian Luo
    Department of Thoracic Oncology, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China. ouyangww73@163.com.
  • Li Liang
    Duke Clinical Research Institute, Duke University, Durham, North Carolina.
  • Wei Liu
    Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, United States.
  • Jianping Hu
    Department of Radiology, The First Affiliated Hospital of Fujian Medical University, 20 ChaZhong Rd, Fuzhou, Fujian, 350005, PR China.
  • Weiwei Ouyang
    Department of Thoracic Oncology, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China. ouyangww73@163.com.